E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Obesity and binge eating disorder |
Obesità e binge eating disorder |
|
E.1.1.1 | Medical condition in easily understood language |
Obesity and binge eating disorder |
Obesità e binge eating disorder |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029883 |
E.1.2 | Term | Obesity |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and handling of disulfiram in the treatment of obese patients with binge eating disorder |
Valutare l’efficacia e la maneggevolezza del disulfiram nel trattamento di pazienti obesi affetti da binge eating disorder |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) obesity (BMI ≥ 30); 2) diagnosis of BED according to the diagnostic criteria of the DSM-IV-TR (APA, 2000); 3) aged between 18 and 65 years; 4) residence throughout the period of the study in a location that allows compliance with scheduled visits; 5) be able to discernment, to understand the purposes of the study, provide appropriate behaviors for its implementation, agree on the protocol on the participation in the study and sign an informed consent 6) normal liver and kidney function demonstrated by blood tests performed within the 3 months prior to enrollment (such as complete blood count, blood glucose, BUN, creatinine, ALT, AST, GGT, serum protein) |
1) obesità (BMI≥30); 2) diagnosi di BED in accordo ai criteri diagnostici del DSM-IV-TR (APA, 2000); 3) età compresa tra i 18 ed i 65 anni; 4) residenza per tutto il periodo dello studio in una località che consenta il rispetto delle visite programmate; 5) essere in grado di intendere e di volere, di comprendere gli scopi dello studio, fornire comportamenti adeguati alla sua realizzazione, concordare sul protocollo, sulla partecipazione allo studio e firmare un consenso informato 6) normale funzionalità epatica e renale attestata da esami ematochimici effettuati nell’arco dei 3 mesi precedenti l’arruolamento (quali emocromo, glicemia, azotemia, creatinina, ALT, AST, GGT, proteinemia) |
|
E.4 | Principal exclusion criteria |
1) Diagnosis of dependence and / or current or lifetime alcohol abuse according to the DSM-IV-TR; 2) diagnosis of a psychotic disorder current or lifetime according to the diagnostic criteria of the DSM-IV-TR; 3) a diagnosis of other medical disorders (severe heart disease, diabetes, cirrhosis, hypothyroidism and / or renal dysfunction) or psychiatric disorder (severe mood disorders, suicidal ideation current or past) that, based on medical judgment, may constitute a danger to the participation of the patient in the study or limit compliance; 4) for women of childbearing potential: pregnant, lactating or non-use of contraceptive methods (oral contraceptives or depot, barrier methods such as condoms or spiral); 5) hypersensitivity to disulfiram; 6) start of a psychotherapy treatment for BED less than 3 months; 7) start of drug therapy with psychoactive drugs (antidepressants, anxiolytics, etc..) By a period of less than one month |
1) Diagnosi di dipendenza e/o abuso di alcol attuale o lifetime in accordo ai criteri diagnostici del DSM-IV-TR; 2) diagnosi di un disturbo psicotico attuale o lifetime in accordo ai criteri diagnostici del DSM-IV-TR; 3) diagnosi di un altro disturbo medico (gravi cardiopatie, diabete, cirrosi, ipotiroidismo e/o nefropatie) o psichiatrico (gravi disturbi dell’umore, ideazione suicidiaria attuale o pregressa) che, in base al giudizio medico, possa costituire un pericolo per la partecipazione della paziente allo studio o limitarne la compliance; 4) per le donne in età fertile: stato di gravidanza, allattamento o mancato utilizzo di metodi contraccettivi (contraccettivi orali o depot, metodi di barriera come spirale o preservativo); 5) ipersensibilità accertata verso il disulfiram; 6) inizio di una psicoterapia terapia per il BED da meno di 3 mesi; 7) inizio di una terapia farmacologica con farmaci psicoattivi (antidepressivi, ansiolitici etc.) da un periodo inferiore a 1 mese |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) frequency of episodes of binge; 2) body weight; 3) possible occurrence of side effects; 4) severity of craving for food; 5) quality of life |
1) frequenza degli episodi di abbuffata; 2) peso corporeo; 3) eventuale comparsa di effetti collaterali; 4) severità del craving per il cibo; 5) qualità della vita |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |